|Home | About | Journals | Submit | Contact Us | Français|
To systematically review the literature regarding safety of disease-modifying drug (DMD) use during pregnancy on perinatal and developmental outcomes in offspring of patients with multiple sclerosis (MS).
A PubMed and EMBASE search up to February 2012 was conducted with a manual search of references from relevant articles. Selected studies were evaluated using internationally accepted criteria.
Fifteen studies identified 761 interferon β-, 97 glatiramer acetate-, and 35 natalizumab-exposed pregnancies. Study quality ranged from poor to good; no study was rated excellent. Small sample sizes limited most studies. Compared with data for unexposed pregnancies, fair- to good-quality prospective cohort studies reported that interferon β exposure was associated with lower mean birth weight, shorter mean birth length, and preterm birth (<37 weeks), but not low birth weight (<2,500 g), cesarean delivery, congenital anomaly (including malformation), or spontaneous abortion. Fewer studies of fair quality were available for glatiramer acetate and natalizumab. Glatiramer acetate exposure was not associated with lower mean birth weight, congenital anomaly, preterm birth, or spontaneous abortion. Natalizumab exposure did not appear to be associated with shorter mean birth length, lower mean birth weight, or lower mean gestational age. No studies examined mitoxantrone or fingolimod exposure. One study of paternal DMD use during conception found no effect on gestational age or birth weight. Few studies examined longer-term developmental outcomes.
Further studies are needed to determine the potential risks associated with preconceptional and in utero DMD exposure in patients with MS. Discontinuation of DMDs before conception is still recommended.
Multiple sclerosis (MS) is a chronic degenerative disease of the brain and spinal cord, typically affecting young adults.1 Several disease-modifying drugs (DMD) including interferon β (IFN-β) 1a and 1b, glatiramer acetate (GA), natalizumab, mitoxantrone, and fingolimod are licensed worldwide to reduce the frequency of clinical attacks with the hope of slowing disability progression.2,3 Women with MS are typically advised to discontinue DMD treatment before conceiving to minimize the risk of fetal harm4; nonetheless, prenatal DMD exposure still occurs, in part because approximately 50% of pregnancies are unplanned.5 To our knowledge, no equivalent guidelines exist for men. Based on animal studies and limited human data (mostly observational postmarketing surveillance studies),6 the US Food and Drug Administration has classified GA7 as pregnancy risk category B (no risk shown in animal studies; no adequate human studies).8 IFN-β,9,10 natalizumab,11 and fingolimod12 as category C (risk shown in animal studies; no adequate human studies),8 and mitoxantrone13 as category D (positive evidence of human fetal risk).8 We systematically reviewed studies investigating the safety of DMD exposure on the immediate perinatal and longer-term developmental outcomes in children of patients with MS.
The International Liaison Committee on Resuscitation (ILCOR) 2010 Evidence Evaluation Template14 was used. This is a validated tool for assessing systematic reviews endorsed by 11 international bodies on cardiovascular health and meets all criteria from “a measurement tool for the ‘assessment of multiple systematic reviews' (AMSTAR).”15
In men or women with MS, does periconceptional or in utero exposure to IFN-β, GA, natalizumab, mitoxantrone, or fingolimod have an effect on perinatal and developmental outcomes in offspring compared with no periconceptional or in utero exposure?
PubMed (1947–February 2012) and EMBASE (1980–February 2012) were searched using the keywords: MS AND [interferon beta; glatiramer acetate; natalizumab; mitoxantrone; fingolimod] AND [pregnancy; conception; child development; spermatozoa; ovum; reproduction; birth; delivery; fetal; neonatal; obstetric]. Alternative terms identified via either database were also included. Keywords were exploded and selected from MeSH terms for PubMed or advanced keyword searches for EMBASE. References from relevant articles were also searched manually. To avoid overlooking important emerging research, we also searched 2010 and 2011 proceedings from the largest conferences covering MS research (the annual meetings of the American Academy of Neurology and the European and Americas Committees of Treatment and Research in Multiple Sclerosis) as a discussion point only, not in the data analysis.
We included studies with the a priori aim of assessing perinatal or developmental outcomes in offspring of men or women with MS exposed to one of the following DMDs during pregnancy of conception: IFN-β (1a and 1b), GA, natalizumab, mitoxantrone or fingolimod. Congenital anomalies included any structural or functional abnormalities present at birth, resulting from malformation, deformation, disruption, or dysplasia. Only English language, peer-reviewed original manuscripts with human subjects were considered for data analysis. No relevant systematic reviews or meta-analyses were identified.
The level and quality of evidence were determined by the study design, sample size, potential bias, statistical analysis, use of controls, and data collection strategy14 (tables e-1 and e-2 on the Neurology® Web site at www.neurology.org). Potential conflicts of interest were noted but were not included in the quality assessment. Each DMD was assigned an ILCOR Class of Recommendation regarding its use during pregnancy (table e-3). Articles were independently selected and reviewed by E.L. and B.W.W., and consensus on disagreements was reached between H.T., E.L. and B.W.W.
Published data were used for this systematic review; hence, no ethical approval was sought.
PubMed yielded 237 hits and EMBASE 278, with 461 unique citations identified. A total of 15 studies were selected (4 prospective cohort,6,16–18 5 retrospective cohort,19–23 and 6 case series24–29 studies) for a total of 761 IFN-β-, 97 GA-, and 35 natalizumab-exposed pregnancies. Study characteristics are summarized in tables 1 and e-4. From the 15 studies analyzed, there were more negative than positive findings reported, and most studies did not appear to have potential conflicts of interest. However, studies with negative findings appeared more likely to have had industry funding support. Overall, the level of evidence ranged from Level 3 to 5 (prospective cohort to case series), and the quality ranged from poor to good (table 2).
Maternal exposure studies reported mixed findings regarding the risk of lower mean birth weight,6,16,18,22 lower mean gestational age,16,22 preterm birth,6,18 and spontaneous abortion.6,18 However, the best evidence (good-quality, Level 3) suggested that IFN-β exposure was associated with lower mean birth weight, shorter mean birth length, and preterm birth (<37 weeks) but not with spontaneous abortion, cesarean delivery, or low birth weight (defined as <2,500 g) (table 3).18 Fair-quality level 3 evidence studies showed no increased risk of lower mean gestational age16 or congenital anomalies6 in IFN-β-exposed births (table 3). Descriptively, the incidence of therapeutic abortion was higher in IFN-β-exposed vs IFN-β-unexposed pregnancies but lower than that for the general population.18,22,28
Based on fair-quality Level 3 evidence, GA exposure was not associated with lower mean birth weight, lower mean gestational age, preterm birth (<37 weeks), congenital anomaly, or spontaneous abortion (table 3).6
No identified studies assessed the safety of mitoxantrone or fingolimod exposure.
Forty-six pregnancies were fathered by 32 men with MS who conceived offspring while being treated with a DMD, resulting in birth weights and lengths comparable to those of the general population (table 1).21 Descriptively, the risk of congenital anomaly and spontaneous abortion was similar to those for pregnancies of mothers from the general population.21
Two studies reported no increased risk of developmental abnormalities associated with IFN-β exposure,18,22 although follow-up was limited to 1 year in one study22 and a median follow-up of 2.1 years in the other.18 One developmental abnormality (inadequate language performance) was described in a case series (Level 5 evidence) of 11 newborns exposed to GA for at least 7 months of gestation.25 No other studies examining longer-term developmental outcomes were found.
Based on an overall assessment of the literature, the following class of recommendation14 was assigned to each DMD for the following reasons:
Of interest, although most pregnant women with MS exposed to IFN-β discontinued therapy early in pregnancy, IFN-β was associated with prematurity and decreased fetal growth, outcomes often associated with adverse events occurring later in pregnancy. Because the first trimester of pregnancy is characterized by rapid cell division and precisely choreographed gene expression that lays the foundation for later fetal growth and development,31 it is entirely possible that early IFN-β exposure may have affected these early processes to cause later prematurity and decreased growth.
Emerging research (published in abstract form only) from 2010 and 2011 conference proceedings regarding IFN-β and GA exposure during pregnancy,32–35 has been largely consistent with the analyzed results of this systematic review. For natalizumab, a case series of 277 exposed pregnancies to mothers with MS found 31 spontaneous abortions and 23 congenital anomalies.36 For fingolimod, 34 exposed pregnancies resulted in 1 case of tibial malformation, 1 case of tetralogy of Fallot (a congenital heart defect), and 5 spontaneous abortions37; authors from both studies concluded that small numbers limited conclusions at present.36,37
Women with MS should still be advised to discontinue DMDs if they are planning to conceive. After unintentional DMD exposure during pregnancy, women should consider discontinuation of their MS drugs. However, mitoxantrone aside, there is currently a lack of evidence to strongly support consideration of pregnancy termination after paternal or maternal exposure to the MS DMDs. Future research should further explore long-term development in offspring exposed to DMDs.
Supplemental data at www.neurology.org
E. Lu: design and conceptualization of the study, analysis and interpretation of the data, drafting and revising the manuscript. B.W. Wang: analysis and interpretation of the data, revising the manuscript. C. Guimond: interpretation of the data, revising the manuscript. Dr. Synnes: design of the study, interpretation of the data, revising the manuscript. Dr. Sadovnick: conceptualization of the study, interpretation of the data, revising the manuscript. Dr. Tremlett: design and conceptualization of the study, analysis and interpretation of the data, drafting and revising the manuscript.
E. Lu is funded by the University of British Columbia (Graduate Entrance Scholarship and Faculty of Medicine Graduate Award), Canadian Institutes of Health Research (Canada Graduate Scholarship: Master's Award), and the Multiple Sclerosis Society of Canada (MSc and PhD Research Studentships). B.W. Wang is funded by the Albert and Mary Steiner Summer Research Award and the Canadian Institutes for Health Research (Professional Student Research Award). C. Guimond reports no disclosures. A. Synnes reports no disclosures. D. Sadovnick has received research support from the MS Society of Canada Scientific Research Foundation, and CIHR and speaker honoraria and/or travel expenses to attend conferences from Biogen-Idec, Merck-Serono, Teva Neurosciences, and Bayer. H. Tremlett is funded by the Multiple Sclerosis Society of Canada (Don Paty Career Development Award) and is a Michael Smith Foundation for Health Research Scholar and the Canada Research Chair for Neuroepidemiology and Multiple Sclerosis. She has also received research support from the US National Multiple Sclerosis Society, CIHR, and UK MS Trust; speaker honoraria and/or travel expenses to speak at conferences from the Consortium of MS Centres, US National MS Society, Swiss Multiple Sclerosis Society, the University of British Columbia Multiple Sclerosis Research Program, Bayer Pharmaceuticals (2010, invited speaker, honoraria declined), and Teva Pharmaceuticals (2011, invited speaker). Unless otherwise stated, all speaker honoraria are either donated to an MS charity or to an unrestricted grant for use by her research group. Go to Neurology.org for full disclosures.